Viridian Therapeutics, Inc. (VRDN) compared with its closest peers (RMTI, LFCR, AYTU, CTMX, ENTA). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Rockwell Medical, Lifecore Biomedical, Aytu BioPharma, CytomX Therapeutics, Enanta Pharmaceuticals, Fortress Biotech, Nuvation Bio, Eton Pharmaceuticals, Tango Therapeutics and Journey Medical share Viridian Therapeutics's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Rockwell Medical, Inc. (RMTI) | $315.76M | — |
| Lifecore Biomedical, Inc. (LFCR) | $172.61M | -15.2 |
| Aytu BioPharma, Inc. (AYTU) | $25.12M | -1.0 |
| CytomX Therapeutics, Inc. (CTMX) | $714.71M | -28.5 |
| Enanta Pharmaceuticals, Inc. (ENTA) | $390.28M | -2.8 |
| Fortress Biotech, Inc. (FBIO) | $95.44M | 0.9 |
| Nuvation Bio Inc. (NUVB) | $2.43B | -14.9 |
| Eton Pharmaceuticals, Inc. (ETON) | $1.81B | 142.9 |
| Tango Therapeutics, Inc. (TNGX) | $3.46B | -10.2 |
| Journey Medical Corporation (DERM) | $213.21M | -16.4 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
VRDN overview · VRDN earnings · VRDN financials · VRDN KPIs · VRDN documents · VRDN ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.